Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q3 FY21 Earnings Presentation
22 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Feb 10, 2021
Slide 1: J. B. Chemicals & Pharmaceuticals Limited
J. B. CHEMICALS & PHARMACEUTICALS LIMITED February 10, 2021 National Stock Exchange of India Ltd. Exchange Plaza, C-1, Block-G, Bandra Kurla Complex Bandra (E) Mumbai 400 051 Scrip Code : JBCHEPHARM Dear Sir, Subject: Investor Presentation Enclosed please find the presentation the Company proposes t
Slide 2: Q3 & 9M FY21 – Financial Results
Q3 & 9M FY21 – FINANCIAL RESULTS JB CHEMICALS AND PHARMACEUTICALS LIMITED
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: Index
Index 4 8 12 Company Overview Q3 & 9M FY21 Historical Financial Financial Performance Performance 3
Slide 5: Company Overview
Company Overview 4
Slide 6: Corporate Snapshot
Corporate Snapshot India field force Years of operations with Brands among top 300 Growth in chronic expanded , significantly 40+ consistent track record across multiple businesses 5 brands, contributing over 80% of domestic formulations revenues 29% therapies* in the domestic formulations business
Slide 7: Domestic Formulations: Outperformance Driven by Strong Brands
Domestic Formulations: Outperformance Driven by Strong Brands Strong performance in chronic therapies JBCPL is the among the fastest Leadership position Chronic Therapies (%) Domestic Formulations* (INR cr) growing pharma companies in the covered markets CAGR: 16% 797 675 671 588 18% Vs market growt
Slide 8: International Business: Clearly Defined Businesses Across Geographies
International Business: Clearly Defined Businesses Across Geographies International Formulations CMO Direct presence in Russia Distributor relationships in the Leading global position in $4.6 bn Marquee global clients in and South Africa US, Asia, Africa and LatAm lozenges market opportunity pharma
Slide 9: CEO's Message
CEO’s Message Nikhil Chopra, CEO, JBCPL on Business Outlook: “Overall, the business continued to show encouraging momentum and registered a very healthy growth rate in Q3. India business continues to witness a positive trend in the chronic segment and we are among the fastest growing companies in IP
Slide 10: Q3 & 9M FY21 Financial Performance
Q3 & 9M FY21 Financial Performance 9
Slide 11: Financial Overview
Financial Overview o Operational and revenue momentum continues – with strong contributions Revenues (INR cr) from Domestic Formulations and International Business 14% o Domestic Formulations maintains secular outperformance compared to 1,514 IPM growth rates, driven by strength in chronic segment
Slide 12: Financial Overview
Financial Overview Profit Before Tax (INR cr) 65% 465 136% 282 209 o Profit Before Tax for Q3 FY21 includes non-recurring income of ~Rs. 34 88 crore related to sale of product registration, marketing authorization along with trademark. The transacted asset has not been contributing to the compan
Slide 13: Revenue Analysis
Revenue Analysis Domestic Formulations* (INR cr) o India formulations business continues to witness healthy trend in the chronic segment – JBCPL remains one of the fastest growing companies as 13% per IPM: 671 595 • Growth driven by key chronic segments of presence – cardiovascular/anti-hypertensi
Slide 14: Q3 & 9M FY21 – Financial Performance
Q3 & 9M FY21 – Financial Performance Particulars (Rs. Crore) Q3 FY21 Q3FY20 YoY Growth 9M FY21 9M FY20 YoY Growth FY20 Revenue from Operations 548.2 428.6 27.9% 1,514.1 1,331.2 13.7% 1,774.7 Cost of Goods Sold 186.9 150.3 24.3% 507.0 483.8 4.8% 630.8 Employee Benefit Expenses 84.7 82.3 2.9% 254.4 23
Slide 15: Historical Financial Performance
Historical Financial Performance 14
Slide 16: Strong revenue growth and margin expansion
Strong revenue growth and margin expansion Revenues (INR cr) CAGR: 12% 1,775 1,643 o Growth acceleration following realignment of go-to-market model 1,413 and expansion of sales force in India with greater focus on chronic therapies o Expansion of global footprint, leveraging existing products along
Slide 17: Accelerated profit growth
Accelerated profit growth Profit After Tax (INR cr) Margin (%) CAGR: 40% 15.3% 11.8% 272 9.9% 194 139 o Growth initiatives delivered on a largely stable capital base through higher utilization of capacities FY18 FY19 FY20 o Debt-free, cash surplus status maintained despite increasing pay-outs to sha
Slide 18: Broad-based growth contribution
Broad-based growth contribution Domestic Formulations* (INR cr) o Consistently outpaced the market by focusing on key brands and chronic therapies CAGR: 16% 797 o Sales Force expansion and divisionalization over the last three years has 675 enabled therapy focus, resulting in: 588 • Top 5 brands imp
Slide 19: Substantial improvements in shareholder returns and consistent cash generation
Substantial improvements in shareholder returns and consistent cash generation ROCE* Net Cash Position (INR cr) 28% 468 435 24% 402 15% FY18 FY19 FY20 FY18 FY19 FY20 Operating Cash Flow (INR cr) Free Cash Flow (INR cr) 275 202 194 145 123 87 FY18 FY19 FY20 FY18 FY19 FY20 18 * ROCE = EBIT/(Net Worth
Slide 20: Save the Date
Save the Date J. B. Chemicals & Pharmaceuticals Limited CORDIALLY INVITES YOU TO A VIRTUAL INVESTOR & ANALYST MEETING, a platform for business and strategic discussions with the Company’s management 2nd March 2021 | 03:30 PM – 06:00 PM IST Registration and log-in details for the event to follow
Slide 21: About J.B. Chemicals & Pharmaceuticals Limited
About J.B. Chemicals & Pharmaceuticals Limited J.B. Chemicals and Pharmaceuticals Limited (JBCPL) (BSE: 506943 | NSE: For further information, please JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization
Slide 22: Thank You
Thank You 21
J. B. Chemicals & Pharmaceuticals — Q3 FY21 Earnings Presentation on 6ix